ArticleKidney international reports2025
Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- eGFR slope improvement with SGLT2 inhibitors is not statistically associated with changes in urinary protein in Japanese CKD patients: a single-center real-world analysis.Clinical and experimental nephrology · 2026Article
- Review no. 2: a beginner's guide for calculating eGFR slope using linear mixed-effects model in R-step-by-step methods and code examples.Clinical and experimental nephrology · 2026Review
- Quantifying Podocyte Depletion and Loss in IgA Nephropathy: A Dual Tissue and Urine Podometric Approach.Kidney360 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dapagliflozin exerts renoprotective effects in patients with IgA nephropathy (IgAN). However, the association between the pretreatment estimated glomerular filtration rate (eGFR) slope and posttreatment outcomes in patients with slowly progressing IgAN with optimal standard care is unclear. Methods: This study included patients with biopsy-confirmed IgAN who were prescribed dapagliflozin during outpatient visits (August 2021-March 2022). Longitudinal eGFR and proteinuria data were analyzed 2 to 3 years before and after treatment. The eGFR slope and time-averaged urinary protein-to-creatinine ratio (UPCR) were compared between the pretreatment period and the posttreatment chronic phase (≥ 90 days). Multivariable regression analysis was performed to examine the association between the pretreatment eGFR slope and posttreatment changes in the slope. Results: A total of 84 patients (median age: 55.5 years; 38% female; median eGFR: 40.0 ml/min per 1.73 m Conclusion: Dapagliflozin was associated with a slower eGFR decline in patients with IgAN, particularly those with a steeper pretreatment eGFR slope, suggesting that pretreatment eGFR slope may help guide individualized therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.